Development of microRNA-based TREATMENTS for MYOTONIC DYSTROPHY Type 1 by Translational Genomics Group

Dr. Artero working on rare diseases

Logo for TATAMI project aiming therapies against myotonic dystrophy

Dr. Artero’s Lab, based in Spain (University of Valencia), is a pioneer in discovering therapeutic targets and innovative drug candidates for rare diseases

VALENCIA, VALENCIA, SPAIN, February 28, 2021 /EINPresswire.com/ — Translational Genomics Group (Dr. Artero’s Lab), a Spanish research laboratory affiliated to the University of Valencia (UVEG) and INCLIVA Biomedical Research Institute, is a pioneer in discovering therapeutic targets and innovative drug candidates for rare diseases, has announced the development of novel DM1 (Myotonic Dystrophy Type 1) therapies based on recent new knowledge on microRNA class molecules. Being the most common muscular dystrophy in adults, affecting around 90,000 people in Europe and 75,000 in the US, the researchers from the Translational Genomics Group announced that their DM therapy could help these people and improve their quality of life.

About Myotonic Dystrophy Type 1

Myotonic dystrophy type 1 (DM1) is a life-threatening and chronically debilitating disease. The estimated incidence of the disorder worldwide is approximately one in 3,000-8,000 people, making it the most frequent adult muscular dystrophy. The disorder is inherited as an autosomal dominant trait, meaning that a child must inherit only one copy of the defective gene from one parent to develop the disease. Individuals born from individuals who are carriers of the mutated gene usually display age anticipation and higher severity for the clinical disease progression. Currently, there is no cure available to arrest or retard disease progression. Therefore, possible treatments are urgently needed since clinical management is limited to symptomatic care.

DM1 displays a wide range for onset of the clinical signs, including neonatal and infantile, to later adult forms being diagnosed. In a common clinical path, DM1 patients always manifest an important degree of progressive locomotor muscle weakness, atrophy, and myotonia, with the addition of less known, but also frequent, respiratory and cardiac impairments connected to other muscles degeneration, eventually leading to premature death, neurological issues causing social disabilities, and features outside the neuromuscular spectrum, including diabetes, cataracts, and higher cancer incidence.

Caused by an expansion of CTG repeats in a non-coding region of the DMPK gene, DM1 was the first disease ever described for which the underlying cause of the pathology involves an RNA-gain-of-function (RNA toxicity) mechanism. Upon transcription, expanded CUG in DMPK mRNAs form stable hairpin structures retained in the cell nucleus where they contribute to the abnormal binding and functional depletion of important factors strongly involved in RNA metabolism. Specifically, the limited availability of Muscleblind-like family factors (MBNLs) is the most significant contribution to DM1 phenotypes, like cardiac conduction problems, myotonia, and insulin resistance. However, the causes of other former critical clinical features in DM1 patients, like the significant muscular atrophy, are still not understood.

About Translational Genomics Group (Dr. Artero’s Lab):

Translational Genomics Group currently aims to identify therapeutic targets and develop innovative treatments for rare neuromuscular diseases (www.uv.es/gt). Very focused on DM1 from the very beginning, Dr. Artero and his team have provided the community with significant scientific advances that are now practical tools to push forward the development of novel drugs against DM1. Thus, their practical and rapid drug screening approaches have helped to identify and validate several chemical compounds, some licensed to the industry, for their further development in DM1. Dr. Artero´s long-term vision is highly relevant and transformative in filling in the gap between drug discovery and development in DM1 by leading the engagement of a multidisciplinary-driven effort to translate the results into actual treatments.

During the last years, Dr. Artero´s research has tracked to the DM1 field new actors to act together in a coordinated manner, intending to move novel candidate drugs to their next step. Research groups from top-notch European institutions such as Oxford University (UK) and CSIC (Spain), involved in medicinal chemistry of therapeutic oligonucleotides; Institute of Myology (France), developing novel animal model experimentation; IBEC (Spain), developing 3D tissue bioengineering; IIS Biodonostia (Spain), studying clinical evolution of the disease, are now directly involved in DM1 research through ongoing multidisciplinary projects like TATAMI (being funded by “la Caixa” Banking Foundation under the project code HR17-00268) or PROMETEO (being funded by regional Valencian Government) both coordinated by Dr. Artero. Significantly, non-scientific stakeholders are also involved in these projects to increase the chances of subsequent efforts, including national (ASEM Federation) and international (Myotonic Dystrophy Foundation) patient associations, research transfer offices, and regulatory CROs. At this moment, Dr. Artero is pursuing the construction of an European network for DM1 translational research with the incorporation of additional partners at scientific and non-scientific levels.

About microRNAs and DM1

In the last years, Dr. Artero’s group has pioneered the deciphering of small RNA regulatory molecules, called microRNAs (miRNAs), on distinct DM1 disease features.

By characterizing the miRNA-linked repression of the endogenous MBNL genes as an overlaid layer of regulation to the MBNL depletion pathway, they found two specific miRNAs (miR-23b and miR-218) that repress the expression of MBNL1 and MBNL2. Thus, the group has designed antisense oligonucleotides (AONs) that block the repressive miRNAs (antagomiRs), which have provided proof-of-concept to improve DM1-like alterations in a mouse model of the disease. Importantly, these results, under patent protection and recently published in the journal Nature Communications, led the creation, at the end of 2019, of a spin-off company of the University of Valencia, ARTHEx Biotech (www.arthexbiotech.com), that rapidly grown the interest of private investors at the bio & health field, completing an initial seed-round of 8M $ for the optimization of the drug candidate, subsequent preclinical regulatory studies, and design of the first clinical trial.

In a parallel research line, Dr. Artero´s group has recently published in Molecular Therapy Nucleic Acids how miR-7 contributes to the muscle atrophy phenotype in DM1 by studying its consequences replenishing or blocking miR-7 by using specific agomiR and antagomiR oligonucleotide molecules, respectively. Importantly, they highlighted that miR-7 dysfunction was linked to the alteration of catabolic muscle processes through autophagy- and atrophy-related pathways and support that restoration of miR-7 levels is a candidate therapeutic target counteracting muscle atrophy in DM1. A broader characterization of the molecular pathway for DM1 muscle atrophy is currently ongoing.

Want to crowdfund us? Contact at mecenzago@incliva.es
Want to collaborate with us? Contact at ruben.artero@uv.es

Rubén Artero Allepuz
Universidad de Valencia (SPAIN)
email us here

TATAMI research project: Trying to win the fight against Myotonic Dystrophy Type 1


Source: EIN Presswire

To Return Falcons to Their Original Habitat..Hadad Program Applauded by Falconry Experts

Mark Upton, the executive secretary of the IAF

Hadad program was founded in 2020 by the SFC

IAF :We would like to support this project in any way we can, through our world-wide knowledge base of raptor conservation projects.”

RIYADH, SAUDI ARABIA, February 27, 2021 /EINPresswire.com/ —

A top official at the International Association for Falconry and Conservation of Birds of Prey (IAF) applauded the Hadad Program founded by the Saudi Falcons Club (SFC) and described it as “a fantastic project”. In an interview Mark Upton, the executive secretary of the IAF said “We would like to support this project in any way we can, through our world-wide knowledge base of raptor conservation projects.” He added that the program “fulfills the conservation and heritage aspirations of falconers around the world.”

This environmental initiative he elaborated aims at the “reintroduction of local falcons within the Kingdom and migratory falcons in Central Asia and releasing them back into their original natural habitats.”

Upton elaborated that volunteers, veterinary experts, international scientists, and Saudi falconers will work together to meet the objectives of the program. He added, “We can only emphasize how important it is that this project is supported by those who wish to maintain the heritage and continuation of traditional falconry in the Kingdom of Saudi Arabia, the Middle East and beyond.”

Having a falconer father who once visited the region, Upton is personally excited about Hadad program, wishing his father is “looking down on it with great enthusiasm.”
According to him falconers were the first to notice the declining number of Peregrine Falcons in the sixties due to the misuse of agricultural chemicals. Hence, they were the first to successfully boost the falcon population and introduce falcons in Europe and North America where they have been extinct.
Now, the numbers of Peregrine Falcons are increasing more than ever before. Falconers have been in the forefront of conversational projects to protecting raptors and their prey that lost their natural habitats.

Upton stressed the IAF is dedicated to the preservation of the ancient art of falconry, and that the association has been involved in the acceptance of falconry as a UNESCO’s intangible cultural heritage of mankind. Founded in 1968 by a small group of falconry clubs from Europe, Japan, and US the IAF now represents thousands of falconers from over 80 countries around the world, including Saudi Arabia.

Hadad program was founded in 2020 by the SFC. The program is the first of its kind in Saudi Arabia that aims to reintroduce local and migratory falcons to their original habitats, increase the falcon population, and strengthen the Kingdom’s pioneering role in protecting the wildlife and natural environment as part of the transformative Vision 2030.

abdulrahman alabsi
SFC
email us here

IAF :We would like to support this project in any way we can, through our world-wide knowledge base of raptor conservation projects.”


Source: EIN Presswire

Advanced Innovative Partners Receives Multiple Rare Pediatric Disease and Orphan Designations from the FDA

SURFSIDE, FLORIDA, UNITED STATES, February 26, 2021 /EINPresswire.com/ — Advanced Innovative Partners (AIP), a privately held life sciences company developing rare disease drugs for cancer, today announced that the U.S. Food and Drug Administration (FDA) granted two rare pediatric disease designations (RPDDs) for programs in its development pipeline, Osteosarcoma and Ewing’s Sarcoma, potentially devastating bone ailments in children. The company has also received orphan drug designations (ODDs), for its Diffuse Intrinsic Pontine Glioma (DIPG) and Acute Lymphoblastic Leukemia (ALL) cancer programs.

AIP is developing innovative technologies enabling the management or treatment of these diseases more effectively. Though rare, Osteosarcoma is the most common type of bone cancer. Ewing sarcoma is another rare oncological disease that presents with lesions in and around bone. Advancements in the treatment of Ewing’s sarcoma is significantly improving outcomes and AIP’s novel technology has the promise of further advancement of diagnosis and treatment.

“Cancers that affects the bones represent significant burdens for patients, their families, and the healthcare systems,” said Roseanne Satz, AIP Chief Executive Officer. “Our innovative platform promises to enable more efficient clinical management of these pediatric diseases, helping physicians to implement the best treatment for children suffering from these cancers. We are proud to have developed these new agents that have potential to enable best-in-class treatments for bone cancer. We greatly appreciate the FDA granting these multiple orphan and rare pediatric disease designations.”

Designation as an orphan drug serves to advance drug development for rare diseases. The FDA grants the designation to drugs or biologics that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. Under the RPDD program, the FDA grants a Priority Review Voucher (PRV) to the sponsor who receives a product approval for a “rare pediatric disease,” defined as a serious or life-threatening condition of fewer than 200,000 Americans that primarily affects individuals from birth to 18 years. AIP may be eligible to receive a PRV for each RPDD that gains marketing approval.

Orphan designation provides development and commercial incentives including exemption from FDA user fees and eligibility for a seven-year period of market exclusivity upon approval in the U.S. The vouchers may be sold or transferred or redeemed for a subsequent marketing application for a different drug enabling accelerated review of a drug application.

About Advanced Innovative Partners

AIP is a clinical stage biotechnology company focused on the development of novel therapeutics and diagnostics in oncology, neurology, rare pediatric and infectious diseases, as well as medical countermeasures. Our vision is to deliver transformative science to underserved patients. Our name symbolizes a mission to partner with clinicians and scientists to help people who are in urgent need.

Juanita Gallego
Advanced Innovative Partners
+1 561-757-8666
juanita.gallego@advancedinnovativepartners.com
Visit us on social media:
Twitter
LinkedIn


Source: EIN Presswire

Transducer Techniques Offers a Group of Highly Accurate Small Load Cells and Force Sensors

CAL-TEDS Plug & Play Smart Sensors Icon

CAL-TEDS Plug & Play Smart Sensors Icon

Load Cell Force Sensor Group

Load Cell Force Sensor Group

MLC Series Load Cell

MLC Series Load Cell

SLB Series Subminiature Load Cells

SLB Series Subminiature Load Cells

THA Series Load Cell

THA Series Load Cell

This group of tiny load cells, comprised of the MLC, SLB, THA, and THD Series, offer force measurement ranges from 25 to 50,000 pounds.

TEMECULA, CALIFORNIA, UNITED STATES, February 26, 2021 /EINPresswire.com/ — Transducer Techniques offers a group of highly accurate small load cells and force sensors. The MLC Series compression only load columns are offered in several ranges from 2,000 pounds to 30,000 pounds. The SLB Series compression only miniature load button load cells range from 25 pounds to 1,000 pounds, and the THA through THD Series compression only thru-hole load cells range from 50 pounds to 50,000 pounds. The accuracy specifications for Linearity, Hysteresis, and Repeatability are consistent with highly accurate strain gage based load cells.

https://www.transducertechniques.com

Transducer Techniques, established in 1979, designs and manufactures a complete line of load cells, torque sensors, special purpose transducers and related instrumentation. Transducer Techniques load cells are uniquely designed for weight and force measurement in such diversified applications as process control and factory automation. Other applications exist in numerous fields of science and industry for our load cells. All transducer sensing elements incorporate bonded foil strain gauges, wired in a full Wheatstone bridge configuration.

Technology
Load cells are electro-mechanical transducers that translate force or weight into voltage. This change in voltage produces a signal in the read-out instrumentation, a repeatable deflection or indication that can be calibrated directly in terms of the load applied to the load cell.

Construction
Construction of the load cell utilizes all the advantages of bonded foil strain gauges. Sealed within the load cell are sets of matched strain gauges bonded to a high strength element, machined to close tolerances. The strain gauges are electrically connected to form a balanced Wheatstone bridge and additional compensation resistors are added to the circuit for maintaining the accuracy of the bridge over a wide temperature range.

Operation
The principle of operation depends upon the deflection of the strain gauge filament, creating a change in its resistance, thereby unbalancing the bridge circuit. As a result, for a given input voltage, the output voltage of the bridge varies proportionally with the load and the change can be read on appropriate instrumentation.

Quality
When completed, each load cell is individually tested and calibrated. Each cell must meet or exceed rigid electrical and mechanical performance tests before it is released for service. Also, every cell is proof tested to its full rated capacity, and in most instances, to over its rated capacity.

Attributes
An important asset of our load cells is their extremely small deflection. The maximum deflection of standard cells does not exceed .012" at full load. This plus the fact that these load cells contain no moving parts opens unlimited application fields. The inherent compactness of the load cells minimizes installation problems.

The frequency response characteristics of our load cells are exceptionally good. The relatively low mass, and the small deflection under load, result in a high-frequency response which emphasizes the use of the load cells in many services where other transducers cannot perform.

Only strain gauges of the highest quality are installed and configured by technicians who have undergone our extensive training program targeting craftsmanship and attention to detail. To the end-user, this means a quality product. All Load Cells / Force Sensors and Torque Sensors are supplied with a Calibration Certificate traceable to NIST.

Customer Support
Transducer Techniques, LLC
+1 800-344-3965
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

From Transducer Techniques the MLP and DPM-3 System is Suitable for a Variety of Industrial Weighing Applications

CAL-TEDS Plug & Play Smart Sensors Icon

CAL-TEDS Plug & Play Smart Sensors

MLP Load Cell and DPM-3 Panel Mount Meter

MLP Load Cell and DPM-3 Panel Mount Meter

MLP Series Load Cell

MLP Series Load Cell

The MLP load cell and DPM-3 Digital Panel Mount Load Cell Meter are great for a variety of force measurements in industrial or laboratory weighing applications.

TEMECULA, CALIFORNIA, UNITED STATES, February 26, 2021 /EINPresswire.com/ — Transducer Techniques has featured an economically priced load cell system comprised of our popular MLP load cell and DPM-3 Digital Panel Mount Load Cell Meter. This system is suitable for a variety of OEM force measurement and industrial or laboratory weighing applications. The DPM-3 can be scaled to a full five digits, samples 60 readings per second, and features true peak reading capability. Available options for the DPM-3 Digital Panel Mount Load Cell Meter include dual relay capability, analog output, and serial communications. The MLP load cell is a tension and compression load cell constructed from stainless steel or aluminum alloy and offered in a variety of ranges from 10 pounds to 1,000 pounds. Accuracy specifications are consistent with high-quality strain gauge load cells.

https://www.transducertechniques.com

Transducer Techniques, established in 1979, designs and manufactures a complete line of load cells, torque sensors, special purpose transducers and related instrumentation. Transducer Techniques load cells are uniquely designed for weight and force measurement in such diversified applications as process control and factory automation. Other applications exist in numerous fields of science and industry for our load cells. All transducer sensing elements incorporate bonded foil strain gauges, wired in a full Wheatstone bridge configuration.

Technology
Load cells are electro-mechanical transducers that translate force or weight into voltage. This change in voltage produces a signal in the read-out instrumentation, a repeatable deflection or indication that can be calibrated directly in terms of the load applied to the load cell.

Construction
Construction of the load cell utilizes all the advantages of bonded foil strain gauges. Sealed within the load cell are sets of matched strain gauges bonded to a high strength element, machined to close tolerances. The strain gauges are electrically connected to form a balanced Wheatstone bridge and additional compensation resistors are added to the circuit for maintaining the accuracy of the bridge over a wide temperature range.

Operation
The principle of operation depends upon the deflection of the strain gauge filament, creating a change in its resistance, thereby unbalancing the bridge circuit. As a result, for a given input voltage, the output voltage of the bridge varies proportionally with the load and the change can be read on appropriate instrumentation.

Quality
When completed, each load cell is individually tested and calibrated. Each cell must meet or exceed rigid electrical and mechanical performance tests before it is released for service. Also, every cell is proof tested to its full rated capacity, and in most instances, to over its rated capacity.

Attributes
An important asset of our load cells is their extremely small deflection. The maximum deflection of standard cells does not exceed .012" at full load. This plus the fact that these load cells contain no moving parts opens unlimited application fields. The inherent compactness of the load cells minimizes installation problems.

The frequency response characteristics of our load cells are exceptionally good. The relatively low mass, and the small deflection under load, result in a high-frequency response which emphasizes the use of the load cells in many services where other transducers cannot perform.

Only strain gauges of the highest quality are installed and configured by technicians who have undergone our extensive training program targeting craftsmanship and attention to detail. To the end-user, this means a quality product. All Load Cells / Force Sensors and Torque Sensors are supplied with a Calibration Certificate traceable to NIST.

Customer Support
Transducer Techniques, LLC
+1 800-344-3965
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

Transducer Techniques TH-Series Load Cells are Intended for Applications Such as Bolt Force Measurements

CAL-TEDS Plug & Play Smart Sensors Icon

CAL-TEDS Plug & Play Smart Sensors Icon

THC Series Compression Load Cell

THC Series Compression Load Cell

THB Series Compression Load Cell

THB Series Compression Load Cell

The TH series are compression only and available in multiple outside diameters of 1.0, 1.5, 2.0, and 3.0 inches.

TEMECULA, CALIFORNIA, UNITED STATES, February 26, 2021 /EINPresswire.com/ — The THA through THD Series thru-hole load cells are intended for applications such as bolt force measurements and overload monitoring. The TH series are compression only and available in multiple outside diameters of 1.0 inch (THA), 1.5 inches (THB), 2.0 inches (THC), and 3.0 inches (THD). The TH Series can also be ordered with a wide variety of inside diameter offerings from 1/8” to 1 1/4”. Please visit our website for OD/ID combinations. Capacities range from 50 pounds through 50,000 pounds and are available with maximum full scale non-linearity of 0.5%. The output specification is a nominal 2 mV/V via a full Wheatstone bridge configuration, using a strain gauge of the highest quality. The TH Series load cells are supplied with a calibration certificate traceable to NIST.

https://www.transducertechniques.com

Transducer Techniques, established in 1979, designs and manufactures a complete line of load cells, torque sensors, special purpose transducers and related instrumentation. Transducer Techniques load cells are uniquely designed for weight and force measurement in such diversified applications as process control and factory automation. Other applications exist in numerous fields of science and industry for our load cells. All transducer sensing elements incorporate bonded foil strain gauges, wired in a full Wheatstone bridge configuration.

Technology
Load cells are electro-mechanical transducers that translate force or weight into voltage. This change in voltage produces a signal in the read-out instrumentation, a repeatable deflection or indication that can be calibrated directly in terms of the load applied to the load cell.

Construction
Construction of the load cell utilizes all the advantages of bonded foil strain gauges. Sealed within the load cell are sets of matched strain gauges bonded to a high strength element, machined to close tolerances. The strain gauges are electrically connected to form a balanced Wheatstone bridge and additional compensation resistors are added to the circuit for maintaining the accuracy of the bridge over a wide temperature range.

Operation
The principle of operation depends upon the deflection of the strain gauge filament, creating a change in its resistance, thereby unbalancing the bridge circuit. As a result, for a given input voltage, the output voltage of the bridge varies proportionally with the load and the change can be read on appropriate instrumentation.

Quality
When completed, each load cell is individually tested and calibrated. Each cell must meet or exceed rigid electrical and mechanical performance tests before it is released for service. Also, every cell is proof tested to its full rated capacity, and in most instances, to over its rated capacity.

Attributes
An important asset of our load cells is their extremely small deflection. The maximum deflection of standard cells does not exceed .012" at full load. This plus the fact that these load cells contain no moving parts opens unlimited application fields. The inherent compactness of the load cells minimizes installation problems.

The frequency response characteristics of our load cells are exceptionally good. The relatively low mass, and the small deflection under load, result in a high-frequency response which emphasizes the use of the load cells in many services where other transducers cannot perform.

Only strain gauges of the highest quality are installed and configured by technicians who have undergone our extensive training program targeting craftsmanship and attention to detail. To the end-user, this means a quality product. All Load Cells / Force Sensors and Torque Sensors are supplied with a Calibration Certificate traceable to NIST.

Customer Support
Transducer Techniques, LLC
+1 800-344-3965
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

Applied Biology and Samel to Inaugurate the First COVID-19 Clinical Research Center in the Brazilian Amazon State

EMERGENT VARIANTS OF SARS-COV-2 IN THE BRAZILIAN AMAZON PRESENT UNIQUE OPPORTUNITY TO STUDY TREATMENTS FOR COVID-19

IRVINE, CA, USA, February 26, 2021 /EINPresswire.com/ — Applied Biology today announced its partnership with Samel – the leading hospital healthcare group in the Brazilian Amazon state.

The Brazilian Amazon state has been a focal point for the emergence of new SARS-CoV-2 variants. Some of the newly emergent strains such as the P1 variant are feared to render treatments and vaccinations significantly less effective. As such, establishing a clinical research center to study emerging variants of SARS-CoV-2 is essential to halt the worldwide pandemic.

According to Dr. Andy Goren, Chief Medical Officer of Applied Biology: “the newly discovered SARS-CoV-2 variants in the Brazilian Amazon are a significant cause of concern in the evolution of the COVID-19 pandemic. We are currently studying a novel anti-androgen as a potential treatment for the newly discovered SARS-CoV-2 variants. We are exploring the expansion of our COVID-19 studies to vaccines.”

According to Luis Alberto Nicolau, CEO of the Samel Group: “our state of the art hospital facility has proven invaluable in saving lives during the first wave of the Pandemic. Combing our knowledge and quality of care with the scientific breakthroughs introduced by Applied Biology, we strive to become a key clinical research center for COVID-19.”

According to Dr. Daniel Fonseca, Medical Director of the Samel Group: “following our collaboration with Dr. Andy Goren in conducting the anti-androgen hospitalized patients study, we have developed the scientific and medical infrastructure to extend our studies to breakthrough therapeutics and vaccines for the treatment of COVID-19.”

For more information, contact customerservice@appliedbiology.com

ABOUT APPLIED BIOLOGY
Founded in 2002, Applied Biology, Inc. (www.appliedbiology.com), headquartered in Irvine, California, is a biotechnology company specializing in hair and skin science. Applied Biology develops breakthrough drugs and medical devices for the treatment of androgen mediated dermatological conditions. Applied Biology's R&D pipeline includes a topically applied prophylactic treatment for chemotherapy induced alopecia; a novel diagnostic device that can aid dermatologists in identifying non-responders to topical minoxidil; an adjuvant therapy for non-responders to topical minoxidil; and a novel therapy for female pattern hair loss.

ABOUT SAMEL GROUP
With more than 40 years of experience in Manaus being a health insurance provider business and hospital with six units – Hospital Samel; Hospital Oscar Nicolau; Hospital Boulevard; Getúlio Vargas Medical Center; São José Medical Center and Via Norte Medical Center – located in different areas of the city, and a seventh hospital unit that is under construction in the Aleixo neighborhood, scheduled to open in 2022, Samel is a genuinely Amazonian group that contributes to the development of the region and is engaged in several projects that benefit local society. With a highly specialized multidisciplinary team that offers 24-hour medical assistance to its more than 110 thousand clients, Samel has certifications that attest to the efficiency of its processes, demonstrating standards of excellence and safety for its clients and professionals at national and international level.

Monica Naegle
Applied Biology, Inc.
+1 949-387-4526
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

New Book on Inspirational Near-Death Experience Achieves #1 Amazon Bestseller Status on Launch Day!

FRESNO, CALIFORNIA, UNITED STATES, February 26, 2021 /EINPresswire.com/ — Ignite Press announced this week that Steven Ross’s new book, Quarks of Light: A Near-Death Experience became a #1 bestseller on Amazon this week in the categories of Near Death Experiences, Organ Transplants, Personal Growth and Christianity, and more!

The book is available on Amazon at https://amzn.to/2LCMWm2

Quarks of Light presents a fascinating, thought-provoking, and inspiring read, offering hope to anyone seeking to overcome adversity or experience a spiritual awakening.

“This story is recorded as I experienced it, and without embellishment,” says Rob. “Some people may criticize it for being fantastical, while others may criticize it for not going far enough in one direction or the other as it pertains to religion. I can only share what I have come to understand—nothing more and nothing less.”

To celebrate the launch of the book, the Kindle version of the book will be on sale for 99 cents for a limited time.

Rob A. Gentile is the son of Italian immigrants. He grew up in Aliquippa, Pennsylvania, where his father worked in a steel mill. Gentile has spent his career as a sales representative in the steel industry while married to his wife Melanie for over thirty years.

Together they have devoted themselves to their daughter with special needs, Maria, who is in her twenties. Throughout her childhood, he grappled with difficult questions about prayer and why children must suffer. Answers came in a sudden and unexpected way—at age fifty-six he had a massive heart attack, then flatlined, and had a near-death experience.

His self-discovery and spiritual awakening continued while waiting to receive a donor heart. Quarks of Light is his first book.

Visit Amazon at https://amzn.to/2LCMWm2 to purchase the book and to learn more!

For booking information, visit https://robagentile.com/contact/

Contact Info:
Rob A. Gentile
https://robagentile.com/contact/

Malia Sexton
Ignite Press
+1 559-477-4202
email us here


Source: EIN Presswire

R3 Stem Cell Wins 2021 Most Outstanding Regenerative Medicine Company Award

stem cell center

best stem cell company

Most Outstanding Regenerative Company 2021

Coming off an Award filled 2020, R3 Stem Cell has now won the Most Outstanding Regenerative Medicine Company Award for 2021.

As we've grown over the past 10 years, our main priority has been the safety of the biologics. With our patient satisfaction remaining at 85% consistently, I'm very proud of that track record!”

— CEO David Greene, MD, MBA

SCOTTSDALE, ARIZONA, USA, February 26, 2021 /EINPresswire.com/ — R3 Stem Cell announced it has won the 2021 Most Outstanding Regenerative Medicine Company Award from Corporate Vision. As a long standing trusted USA and international provider of regenerative therapies, the company consistently maintains high patient satisfaction and an unparalleled safety record.

With over 16,000 procedures performed worldwide in the past decade, R3 Stem Cell has become the worldwide leader in stem cell and exosome therapies. R3 International offers stem cell treatments for autism, MS, ALS, diabetes, stroke, kidney/heart/liver failure, Lyme, dementia and more.

According to Dr. David Greene R3 Stem Cell CEO, "As we've grown over the past 10 years, our main priority has been the safety of the biologics. The quality assurance of the stem cell and exosome biologics has been paramount, and as a result we've never had a significant adverse event!"

R3 Stem Cell offers over 35 Centers of Excellence in the USA, and currently has six International Centers in Mexico, Pakistan and Honduras. More countries are in the works. Internationally, the regenerative treatments are offered by either injection, intravenous, intrathecal, nebulizer, intramuscular, intralymphatic or intranasal. Over twenty protocols are offered, depending on the particular patient's condition and severity.

How many stem cells and exosomes a particular patient receives depends also on a patient's condition and its severity. It ranges from 30 million cells, upwards to a billion.

R3 Stem Cell Dr. David Greene added, "Hearing patients rave about how well they are doing after procedures and also complimenting our staff is so gratifying to our team. A lot of our patients come from referrals now, which is directly attributed to the quality of care!"

A few years ago, the R3 Heroes Program was started. The program offers free regenerative therapies to military veterans who are nominated by either themselves, friends or family. The ailments do not need to be service related. To date, over 100 Heroes have been treated in the program.

For anyone interested in seeing whether or not he or she is a candidate for regenerative therapy, simply call (844) GET-STEM to get set up with a free phone consultation.

David Greene, MD, MBA
R3 Stem Cell
+1 844-438-7836
email us here

The Best Stem Cell Clinics


Source: EIN Presswire

Rare Disease Awareness Day Critical As Patients Struggle During COVID Times

Rare Disease Awareness Day

Fibrolamellar Cancer Foundation

Major obstacles have included a delay in diagnoses, limited access to treatments, and the lack of clinical trials.

In addition to missed or postponed monitoring with healthcare providers and research lab closures, the delays in clinical trial launches has limited advancement in treatment options.”

— John Hopper, President of FCF

GREENWICH, CT, UNITED STATES, February 26, 2021 /EINPresswire.com/ — National Rare Disease Awareness Day (RDAD) takes place during the last week of February. This year, the awareness message is even more critical. The pandemic has caused numerous difficulties for rare disease patients, families, and the healthcare community.

Major obstacles have included a delay in diagnoses, limited access to treatments, and the lack of clinical trials.

Helping to spread the word on awareness is Greenwich, CT- based, Fibrolamellar Cancer Foundation (FCF), a non-profit organization formed to fund research, build awareness and provide patient support for an aggressive liver cancer that strikes teens and young adults who are typically not diagnosed until the disease is in an advanced stage. FCF was founded in 2009 by 27-year-old Tucker Davis, who lost his life to Fibrolamellar on Rare Disease Day in 2010, after an 18-month fight.

Fibrolamellar is a prime example of an overlooked, urgent rare disease with no known effective systemic therapies.

John Hopper, President of FCF, has become a national leader in championing the rare disease concerns, said, “This year has been challenging for everyone, but the impact on patients of rare diseases has been especially problematic. In addition to missed or postponed monitoring with healthcare providers, research lab closures, and delays in clinical trial launches has limited advancement in treatment options. It’s vital that the funding for research improves.”

Fibrolamellar patient advocate, Mark A. Carles, 26, of Staten Island, NY, spoke about his fight with the disease and his challenges over the past year. “I’ve had delays with some appointments and treatments because some of my doctors are also needed in COVID wards and the hospitals are only allowed a limited number of beds.”

Carles, a once healthy triathlete and graduate student, was diagnosed in October 2018. He had looked forward to a new clinical trial treatment last year. “COVID pushed back a clinical trial, but COVID wasn’t slowing the growth of my cancer,” he explained.

In August, Carles had another surgery and is currently being treated with chemotherapy and radiation. The check-ups on his current treatment are different as well. “I’ve had to become an expert at Zoom because it’s the only way for my family to be with me during my appointments with the doctors. It’s not the same, but technology has been very helpful.” Carles noted that the FCF and various fibrolamellar patient led Facebook groups, where patients can share resources, experiences, and provide support to one another, has been particularly helpful during COVID.

“We are hoping that Mark’s message spreads nationwide, and worldwide. The pandemic is causing a disruption in the timeliness of care and help for patients. The awareness for people suffering from rare diseases is more important than ever,” Hopper said. “Getting more of the population aware of these struggles can mean more active research and funding that will make a significant difference for treatments and possible cures.”

Fibrolamellar, like many rare diseases, may sound unfamiliar, but when rare diseases combine as a category, the numbers are staggering. One in 10 people are diagnosed with a rare disease and less than 5% of the 7,000+ rare diseases have an FDA approved treatment. However, if funded, rare disease research often leads to breakthrough discoveries, cures and broad-based common healthcare treatments.

Fibrolamellar joins the voice of the 30 million Americans who are fighting rare diseases on National Rare Disease Day to amplify the cause. According to The National Organization of Rare Diseases (NORD) the struggles during the pandemic have included:
• The inability to conduct or participate in clinical trials
• 79% of patients experiencing canceled medical appointments
• 32% of patients having difficulty accessing medical care and treatment
• 14% of patients with issues accessing medication
• 37% of families impacted by a loss of income and 12% of whom can no longer afford medication

This week, Fibrolamellar is featured for Rare Disease Awareness Day at the Connecticut State Capital, with Hopper co-emceeing the state’s RDAD celebration.

About the National Organization for Rare Disorders (NORD):
The National Organization for Rare Disorders (NORD) is the leading independent advocacy organization representing all patients and families affected by rare diseases. NORD is committed to the identification, treatment and cure of the more than 7,000 rare diseases, of which approximately 90% are still without an FDA-approved treatment or therapy. Visit rarediseases.org.

About Fibrolamellar Cancer Foundation:
FCF, a public 501c3 nonprofit organization based in Greenwich, CT, was founded in 2009 by 27-year-old Tucker Davis, who lost his life to Fibrolamellar on Rare Disease Day in 2010, after an 18-month fight. FCF has funded over $8 million in research across more than 24 major institutions in the U.S. and internationally. 100% of all donations go towards research. All FCF’s overhead and administrative costs are paid by the Charles A. and Marna Davis Foundation and Stone Point Capital. For more information, visit www.fibrofoundation.org and also interact with us on our social media channels: Facebook, Twitter and Instagram.

Greg Walsh
Fibrolamellar Cancer Foundation
+1 203-292-6280
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire